Shares of Carisma Therapeutics Inc. (NASDAQ:CARM – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $1.9250.
A number of brokerages recently commented on CARM. D. Boral Capital restated a “buy” rating and issued a $1.00 price target on shares of Carisma Therapeutics in a research report on Friday, August 8th. Evercore ISI upgraded Carisma Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Carisma Therapeutics in a research report on Wednesday.
Get Our Latest Stock Analysis on CARM
Insider Activity at Carisma Therapeutics
Institutional Trading of Carisma Therapeutics
An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 0.36% of Carisma Therapeutics at the end of the most recent quarter. Institutional investors own 44.27% of the company’s stock.
Carisma Therapeutics Stock Performance
Shares of NASDAQ CARM opened at $0.15 on Wednesday. Carisma Therapeutics has a 52 week low of $0.14 and a 52 week high of $1.27. The stock has a market capitalization of $6.43 million, a P/E ratio of -0.10 and a beta of 2.06. The stock’s fifty day moving average is $0.29 and its 200 day moving average is $0.30.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
Read More
- Five stocks we like better than Carisma Therapeutics
- What Does Downgrade Mean in Investing?
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- How to Buy Cheap Stocks Step by Step
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.